1. Sadighbayan D, Sadighbayan K, Tohid-Kia MR, Khosroushahi AY,Hasanzadeh M. Development of electrochemical biosensors for tumormarker determination towards cancer diagnosis: Recent progress.TrACTrends in Analytical Chemistry. 2019;118:73-88.
2. Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancerearly diagnosis.World J Gastroenterol. 2019:25(17):2029.
3. Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries.CA Cancer J Clin.2021:71:209-249. https://doi.org/10.3322/caac. 2166
4. Erridge S, Lyratzopoulos G, Renzi C, Millar A, Lee R. RapidDiagnostic Centres and early cancer diagnosis.British J GeneralPractice.2021;71(712):487-488.
5. Chaturvedi VK, Singh A, Singh VK, Singh MP. Cancer nanotechnology:a new revolution for cancer diagnosis and therapy.Curr DrugMetab.2019;20(6):416-429.
6. https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2017-turkiye-kanser-i-statistikleri.html
7. https://www.drozdogan.com/turkiye-kanser-istatistikleri-2020/
8. Huang Y,Yang S,Zhang J,et al.MicroRNAs as Promising Biomarkersfor Diagnosing Human Cancer.Cancer Investigation. 2010;28:6:670-671.
9. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit RevClin Lab Sci. 2001;38:225-262. Doi.10.1080/20014091084218
10. https://www.turkbiyokimyadernegi.org.tr/upload/48/Dosyalar/tmp/201837165221.pdf
11. Duffy MJ: Tumor markers in clinical practice: a review focusingon common solid cancers. Med Princ Pract. 2013;22:4-11. Doi.10.1159/000338393
12. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers:a diagnostic tool. Natl J Maxillofac Surg. 2016;7(1):17-20. doi:10.4103/0975-5950.196135
13. Sharma S. Tumor markers in clinical practice: General principles andguidelines. Indian J Med Paediatr Oncol. 2009;30(01):1-8.
14. Nah EH, Cho S, Park H, Kim S, Kwon E, Cho HI. Establishment andvalidation of reference intervals for tumor markers (AFP, CEA, CA19-9,CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary carecenters in Korea: a cross-sectional retrospective study.Health ScienceReports. 2023;6(2):e1107.
15. Grenache DG. Progress in understanding the use of humanchorionic gonadotropin as a tumor marker.Clin Chem Lab Med(CCLM).2020;58(3):323-325.
16. Eriksson B, Öberg K, Stridsberg M. Tumor markers in neuroendocrinetumors. Digestion 2000;62(suppl 1):33-38. doi: 10.1159/000051853
17. Çelik S, Aslan G. Testis tümör belirteçleri ve tanı modelitelerindekigüncel gelişmeler.Kanser Gündemi Dergisi. 2020;8(2):13-18.
18. Gündoğdu Ü. Gastrointestinal ve meme malign neoplasmlıpreoperatif hastalarda, CEA, CA 19-9, CA 15-3, CA 125 ve AFPtümör biyobelirteçlerinin prognostik değeri.Euroasia J Mathematics,Engineering Nat Med Sci. 2020;7(11):88-95.
19. Alanbay İ, Çoksüer H, Ercan CM. Jinekolojik onkolojide tümörbelirteçleri: Literatür Derleme.Kocatepe Tıp Dergisi.2011;12(3):57-163.
20. Sisinni L, Landriscina M. The role of human chorionic gonadotropinas tumor marker: biochemical and clinical aspects. In: Scatena, R. (eds)Advances in cancer biomarkers. Advances in Experimental Medicineand Biology. 2015:867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_11
21. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as abiomarker for breast cancer.Clin Chim Acta. 2010;411(23-24):1869-1874. doi:10.1016/j.cca.2010.08.039
22. Üçüncü MZ. Kolorektal kanserlerin tanı ve prognostik takibinde eskive yeni serum biyobelirteçleri: sistematik inceleme ve meta-analiz.İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2019;9:902-919.Doi: 10.38079/igusabder.592956
23. Hall C, Clarke L, Pal A, et al. A review of the role of carcinoembryonicantigen in clinical practice.Ann Coloproctol. 2019;35(6):294-305.doi:10.3393/ac.2019.11.13
24. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer:Is it clinically useful?Clin Chem 2001;47(4):624-630,https://doi.org/10.1093/clinchem/47.4.624
25. Çetinkaya M, Erdoğan Ö, Deliktaş H, Şahin H. Prostat spesifik antijen(PSA). Muğla Sıtkı Koçman Üniv Tıp Derg. 2015;2(2),67-77. Retrievedfrom https://dergipark.org.tr/tr/pub/muskutd/issue/ 34649/382831
26. Özman O, Talat Z, Erözenci A. Prostat spesifik antijen’in tarihi.”MersinÜniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik TıpDergisi. 2019;9(2):184-188.
27. Yencilek F, Koca O, Kuru M. Prostat kanserinde tanı. Nucl Med Semin.2018;4(3):163-173.
28. Burak Z, Tamer F, Gümüş M. Tiroid kanseri izleminde tiroglobulinölçümünün yeri ve önemi. Nucl Med Semin 2021;7:47-54.
29. Passek K, Zulauf N, Bendels MH, Quarcoo D, Oremek GM. The tumormarker thyroglobulin.Zentralblatt für Arbeitsmedizin, Arbeitsschutzund Ergonomie. 2020;70:40-43.